Skip to main content

Advertisement

Table 2 Hepcidin and risk of RBC transfusion with IV iron therapy

From: Hepcidin predicts response to IV iron therapy in patients admitted to the intensive care unit: a nested cohort study

Variable IV iron Placebo Risk ratio (95% CI) p value
Hepcidin ≤ 53.0 μg/L
 Number RBC units/patients 38/44 80/44   
 Median RBC units (IQR) 1 (0–2) 1 (0–3) 0.48 (0.26–0.85) 0.013
Hepcidin 1st tertile (0–20.1 μg/L)
 Number RBC units/number patients 23/22 35/21   
 Median RBC units (IQR) 1 (0–2) 0 (0–2) 0.63 (0.26–1.50) 0.293
Hepcidin 2nd tertile (20.1–53.0 μg/L)
 Number RBC units/number patients 15/22 45/23   
 Median RBC units (IQR) 0 (0–1) 1 (0–3) 0.35 (0.16–0.77) 0.009
Hepcidin 3rd tertile (> 53.0 μg/L)
 Number RBC units/number patients 43/22 34/23   
 Median RBC units (IQR) 1 (0–3) 1 (0–3) 1.33 (0.57–3.08) 0.518
  1. RBC red blood cell, IQR interquartile range